To learn more, please call our Research Department at (513) 936-5388 or (888) 649-4800. Or email abradley@ohcmail.com
| Locally advanced/metastatic, first line |
| Study number: |
GI 149 Amgen, Inc. 20080259 |
| Protocol title: |
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Pegfilgrastim Administered to Subjects with Locally Advanced or Metastatic Colorectal Cancer Treated with 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI) and Bevacizumab |
| Status |
Open
|
| Metastatic 2nd Line |
| Study Number: |
GI 141 IMCL CP 20-0801 ImClone Systems, Inc. |
| Protocol title: |
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5-FU/FA and Oxaliplatin (mFOLFOX6) in Combination with IMC-1121B or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients with Metastatic Colorectal Cancer following Disease Progression in First-line Irinotecan-based Therapy |
| Status: |
Open |
| Refractory 2nd Line |
| Study Number: |
GI 142 Perifosine 343 Keryx/AOI Pharmaceuticals |
| Protocol title: |
A Phase III Randomized Double-blind Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer |
| Status: |
Open |